Health Check-Up Industry

The global health check-up market was valued at USD 48.71 billion in 2022 and is anticipated to experience a robust growth rate, projected at a compound annual growth rate (CAGR) of 5.3% from 2023 to 2030. This growth can be largely attributed to several factors, including the rising prevalence of chronic diseases, increased investments from government agencies to implement population medical screening initiatives, and a growing adoption of telemedicine and home-based healthcare services. A notable example is the initiative launched by the Indian Health Ministry in May 2023, aimed at providing medical screening for individuals suffering from hypertension and diabetes. This program is designed to deliver standardized care to approximately 75 million individuals grappling with non-communicable diseases by the year 2025.

The COVID-19 pandemic has also played a significant role in shaping the health check-up market, particularly through the introduction of telemedicine in general healthcare practices. This shift has stimulated the home-based testing market and reinforced the digital connectivity framework within the healthcare ecosystem. Furthermore, the increasing incidence of life-threatening diseases remains a critical driver for the industry. Non-communicable diseases, such as diabetes, hypertension, cancer, and cardiovascular diseases, have been on the rise, often remaining asymptomatic in their early stages. For instance, an article from the AMGA indicates that more than 30% of the U.S. population is affected by prehypertension, which significantly raises the likelihood of developing high blood pressure. Regular health check-ups empower individuals to effectively manage these conditions, especially considering that only 1 in 4 U.S. adults currently have their hypertension under control.

In response to the growing health crisis, various government bodies are implementing initiatives aimed at screening target populations for different medical conditions. For example, the U.S. Preventive Services Task Force (USPSTF) recommends annual blood pressure screening for all adults aged 18 and older to better manage risks associated with hypertension. Likewise, Middle Eastern countries have started medical screening programs to enhance public awareness regarding the rising prevalence of hypertension. A pertinent initiative occurred in May 2023 when the Ministry of Health and Prevention (MoHAP) in the UAE launched a national campaign focused on the early detection of hypertension. The UAE aims to achieve a 30% reduction in high blood pressure prevalence by 2030. Consequently, the increasing recommendations and proactive measures from government agencies are expected to be key drivers of growth in the global health check-up market.

Gather more insights about the market drivers, restrains and growth of the Health Check-Up Market

Test Type Insights

In 2022, blood glucose tests held the largest market share at 21.91%:

• This dominance is driven by the increasing global incidence of diabetes.
• Blood glucose tests, such as fasting blood sugar (FBS) and oral glucose tolerance tests (OGTT), are essential for the diagnosis and ongoing monitoring of diabetes.
• Early detection of diabetes enables timely intervention and effective disease management, helping to prevent or delay the onset of diabetes-related complications.
• According to the National Center for Chronic Disease Prevention and Health Promotion, nearly 96 million U.S. adults have prediabetes, and the average prevalence rate of prediabetes has risen by 3% from 2013 to 2020.
• The increasing prevalence of prediabetes and diabetes worldwide is expected to create significant growth opportunities for market players in the global blood glucose testing segment.

The tumor biomarkers segment is projected to have the fastest growth rate during the forecast period:

• Tumor biomarker tests are used to identify individuals at higher risk of developing cancer, based on their biomarker profiles, family history, or other risk factors.
• These biomarkers provide crucial insights into molecular characteristics, aiding in the development of targeted treatments for cancer.
• The incorporation of novel tumor biomarker tests into preventive and specialized health check-up plans is anticipated to drive the growth of the tumor biomarkers segment in the coming years.

Order a free sample PDF of the Health Check-Up Market Intelligence Study, published by Grand View Research.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com/

Follow Us: LinkedIn | Twitter